Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest ACE inhibitor Stories

2008-09-05 03:00:06

By Gutierrez, Orlando M Tamez, Hector; Bhan, Ishir; Zazra, James; Tonelli, Marcello; Wolf, Myles; Januzzi, James L; Chang, Yuchiao; Thadhani, Ravi BACKGROUND: Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are associated with increased cardiovascular mortality in chronic hemodialysis patients. Previous studies focused on prevalent dialysis patients and examined single measurements of NT-proBNP in time. METHODS: We measured NT-proBNP concentrations in 2990...

2008-08-31 12:00:00

31 August, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") announces that the Phase III outcome trial GISSI-Heart Failure demonstrated that Omacor(R) reduced mortality and morbidity in patients with congestive heart failure (CHF). Both primary endpoints were met in the 7000 patient trial. The results were presented today at the European Society of Cardiology (ESC) Hot Line session in Munich, Germany. The findings were also published in The...

2008-07-28 18:00:17

By John von Radowitz Commonly used blood pressure drugs could prove to be powerful new weapons against Alzheimer's, new research has suggested. Scientists found that the drugs, known as angiotensin receptor blockers (ARBs), both prevented the disease occurring and slowed its progression. The effect was "striking", according to the US researchers who reported their findings at an Alzheimer's conference in Chicago. A database at the US Department of Health Systems Veterans Affairs...

2008-06-17 03:00:10

By Forfia, Paul R Mathai, Stephen C; Fisher, Micah R; Housten-Harris, Traci; Hemnes, Anna R; Champion, Hunter C; Girgis, Reda E; Hassoun, Paul M Rationale: Hyponatremia is associated with decompensated heart failure and poor prognosis in patients with left ventricular systolic dysfunction. Objectives: We sought to determine if hyponatremia is associated with right heart failure and worse prognosis in patients with pulmonary arterial hypertension (PAH). Methods: We prospectively followed...

2006-12-19 03:00:09

BASEL, Switzerland and BRIDGEWATER, N.J., Dec. 19, 2006 (PRIME NEWSWIRE) -- Speedel (SWX:SPPN) announced today that in the interests of patient safety it has stopped the current pivotal Phase III clinical trial of SPP301 (Avosentan) in diabetic nephropathy (diabetic kidney disease). This decision was taken by the ASCEND(1) trial's Steering Committee based on a recommendation from the Data Safety Monitoring Board to stop the trial, following a significant imbalance in fluid retention in...

2006-06-08 12:42:15

By Gene Emery BOSTON (Reuters) - A class of widely used blood pressure drugs once considered safe in the early stages of pregnancy can nearly triple the risk of birth defects, a study showed on Wednesday. The drugs, known as ACE inhibitors, were only thought to cause problems when taken after the third month of pregnancy. But the study of nearly 30,000 births logged in Tennessee's Medicaid program and published in this week's New England Journal of Medicine shows the risk exists...

2006-01-09 18:16:13

NEW YORK (Reuters Health) - Patients with coronary artery disease (CAD) are now more likely to use evidence-based therapies than they were a few years ago, but room for improvement still exists, new research indicates. In particular, efforts are needed to increase patients' long-term adherence to treatment. Between 1995 and 2002, the percentage of CAD patients using agents with a proven survival benefit increased each year. However, the report shows that many patients are still not...

2005-09-23 17:20:00

WASHINGTON D.C., Sept. 23 "“ For the first time, researchers have mapped a genetic location that explains why certain blood pressure-lowering drugs aren't effective for some people, according to researchers at the 2005 American Heart Association High Blood Pressure Research meeting. "The findings bring us a step closer to developing targeted therapies for patients with high blood pressure who might otherwise be started on medications that won't help," said lead author Sandosh...

2005-09-08 13:42:59

NEW YORK (Reuters Health) - Kidney damage is a constant danger for people with diabetes, especially when their blood pressure is high. Now European researchers report that the addition of a drug, spironolactone, to standard blood pressure-lowering therapy for such patients helps reduce both blood pressure and the amount of albumin protein in urine, a measure of kidney impairment. Dr. Kaspar Rossing of Steno Diabetes Center in Gentofte, Denmark, and colleagues note in the medical...

2005-09-06 15:44:38

By Anthony J. Brown, MD NEW YORK (Reuters Health) - After people suffer a stroke, lowering their blood pressure can slow or even stop the progression of lesions in the brain, new research suggests. The areas of damage are called white matter hyperintensities, or WMHs, because they show up brightly on MRI, and they have been linked to the development of dementia and depression. "Several studies have linked WMHs with hypertension, but it was unknown if blood pressure lowering could...